A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.

Trial Profile

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2017

At a glance

  • Drugs Phentermine/topiramate (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms SEQUEL
  • Sponsors VIVUS
  • Most Recent Events

    • 02 May 2017 New trial record
    • 28 Apr 2017 Results (n=3040) assessing efficacy and safety of phentermine/topiramate extended release for weight loss in overweight and obese patients using pooled data from CONQUER, EQUIP and SEQUEL trials, published in the Diabetes Care
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top